Abstract: A valve train component for conveying valve actuation motions within an internal combustion engine is provided, which valve train component comprises a body member having a bore formed therein; a sliding member disposed in the bore; and an overload feature operatively connected to the body member and the sliding member. The overload feature is configured to not yield when a load placed on the overload feature is less than a load threshold, thereby preventing movement of the sliding member into the bore, and to yield when a load placed on the overload feature meets or exceeds the load threshold, thereby permitting movement of the sliding member into the bore such that at least a portion of the valve actuation motions is not conveyed by the valve train component.

Abstract: The present disclosure relates to oral dosage forms of pharmaceutical formulations that comprise an antiviral nucleoside, one or more compression aids, one or more glidants, and one or more lubricants, and one or more disintegrants, wherein the oral dosage form is a pellet having a diameter of less than or equal to 4.0 mm.

Abstract: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.

Abstract: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.

Abstract: The invention relates to a tyre (1), the tyre (1) comprising: a tread (2) having a tread surface (3) for contacting the ground and at least one groove-like recess (4) therein forming a free space (5), the recess (4) having a longitudinal extension A along the surface (3) and a depth B measured in a radial direction with respect to a radial axis (X) of the tyre (1) from the tread surface (3) to a radially innermost position (19), wherein the free space (5) can be divided into a sipe portion (6) opening to the tread surface (3) and a groove portion (7) located radially inwards the sipe portion (6), wherein in a cross sectional view transverse to the longitudinal extension A of the recess (4) the groove portion (7) has a groove contour (9), with a longitudinal axis (X?), wherein a corresponding width of the groove contour (9) has a local maximum Wg at a height H referred to a spatial extent E of the groove contour (9) in the direction of this longitudinal axis (X?) and wherein the groove portion (7) has at least

Abstract: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.

Abstract: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.

Abstract: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.

Abstract: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.

Abstract: The present invention relates to certain DPP-4 inhibitors for treating and/or preventing oxidative stress, vascular stress and/or endothelial dysfunction as well as to the use of such DPP-4 inhibitors in treatment and/or prevention of diabetic or non-diabetic patients, including patient groups at risk of cardiovascular and/or renal disease.